

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Premarin 0.625 mg/g Vaginal Cream (DIN 02043440) manufactured by Pfizer Canada ULC, Estragyn 1 mg/g Vaginal Cream (DIN 00727369) will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. The following grouping was added to the Critical Supply Product List **July 14, 2021**.

As of **July 14, 2021**, all claims for Estragyn 1 mg/g Vaginal Cream (DIN 00727369) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Importation of USA-Depo-Provera 150 mg/ml Injection due to Shortage

Due to the shortage of Depo-Provera 150 mg/ml Injection (medroxyprogesterone acetate) in Canada, Health Canada has allowed the importation of Pfizer's USA labelled Depo-Provera 150 mg/ml Injection. This medication has been added to Health Canada's List of Drugs for Exceptional Importation and Sale in Canada.

Please note: A temporary Product Identification Number has been assigned to Depo-Provera 150 mg/ml Injection (PIN: 09858134) effective as of August 4, 2021.

US-labelled Depo-Provera 150 mg/ml Injection, manufacturer by Pfizer Canada, contains the same active ingredient and is the same route of administration as the Canadian-labelled Depo-Provera 150 mg/ml Injection that was authorized and marketed for sale in Canada.

Pharmacists and other health care professionals are reminded:

- The US-labelled Depo-Provera 150 mg/ml Injection is labelled in English only. The French-translated text of the US prefilled syringe inner and outer labels and a link to the French-translated US Prescribing information of the label, Product Information, Consumer Medicine Information and Letter of Introduction for the US-labelled product are available on Pfizer Canada's website at the following link:
https://www.pfizer.ca/sites/default/files/202106/USPI-PPI_Depo-Provera_CI-medroxyprogesterone-acetate-IM_Injection_FR.pdf
- To consult the US Prescribing Information for Indications and Dosage and Administration at
https://www.pfizer.ca/sites/default/files/202106/Signed_Final_DHCPL_Depo-Provera_28June2021_EN.pdf

continued next page

continued from previous page

- To consult the Canadian Product Monograph for Contraindications, Serious Warnings and Precautions Box, and Warnings and Precautions for Depo-Provera 150 mg/ml Injection on Health Canada's Product Monograph at https://pdf.hres.ca/dpd_pm/00043883.PDF
- To review Pfizer Canada's Dear Health Professional Letter issued June 28, 2021 for further details regarding their US-labelled Depo-Provera 150 mg/ml Injection at https://www.pfizer.ca/sites/default/files/202106/Signed_Final_DHCPL_Depo-Provera_28June2021_EN.pdf
- That the vials must be stored upright at controlled room temperature 20° to 25°C (68° to 77°F)

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of the following product, Depo-Provera 150 mg/ml Injection (Temporary PIN **09858134**) will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

DIN	Product Description
00585092	Depo-Provera 150 mg/ml Injection

As of **August 4, 2021**, all claims for the following product will be adjudicated to the price of **\$31.6900 per syringe**.

PIN	Product Description
09858134	Depo-Provera 150 mg/ml Injection

Alberta Blue Cross will continue to monitor the availability of the shorted products and potential alternatives, in addition to working with other provinces and territories, manufacturers and Health Canada to address this shortage and minimize the impact on Albertans.

This product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health to remain as a benefit.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

